Rheumatoid Arthritis Epidemiology and Market Landscape
Rheumatoid Arthritis has a worldwide prevalence of about 1% with an annual incidence of approximately 3/10,000 adults. Similarly, as per the study conducted by Alan J. Silman et al., “the prevalence of Rheumatoid Arthritis is relatively constant in many populations, at 0.5–1.0%. However, a high prevalence of Rheumatoid Arthritis has been reported in the Pima Indians (North American Indians) (5.3%) and in the Chippewa Indians (6.8%). In contrast, low occurrences have been reported in populations from China and Japan”.
As of now, there is no permanent cure for Rheumatoid Arthritis; however, early treatment and support options can manage its progression and the risk for joint damage and swelling. At present, the main treatment options for Rheumatoid Arthritis include medicine, supportive treatments, surgery (to correct any joint problems that develop over a period of time).
Worldwide, key companies in the Rheumatoid Arthritis treatment market including GlaxoSmithKline, Gilead, Galapagos NV, R-Pharm, Taisho Pharmaceuticals, Aclaris Therapeutics, Viela Bio, Bristol Myers Squibb, AbbVie, Pfizer, Philogen, Merck KGaA, Genentech, UCB Pharma, Pra Health Sciences, Izana Bioscience, Takeda, Abivax S.A, Hope Biosciences, and several others are working in the development of therapies.
In the coming years, the launch of emerging therapies in Rheumatoid Arthritis market is expected to significantly improve the health outcome for the people affected with it.
Source: Rheumatoid Arthritis Epidemiology and Market Landscape